Granules India receives EIR from USFDA for Jeedimetla facility

31 May 2016 Evaluate

Granules India has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Jeedimetla facility in December 2015.

The USFDA has acknowledged receipt of its responses sent on January 7 and March 28, 2016 on the observations issued by it for the Jeedimetla facility. The USFDA closed the matter and issued EIR for the Jeedimetla facility situated in the state of Telangana.

Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.


Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.